Cytosorbents Corp
CTSO
查看详细走势图
0.637USD
-0.008-1.26%
收盘 12/19, 16:00（美东）报价延迟15分钟
39.99M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.26%
5天
-6.85%
1月
+2.35%
6月
-46.03%
今年开始到现在
-30.02%
1年
-30.40%
查看详细走势图
TradingKey Cytosorbents Corp股票评分
单位: USD 更新时间: 2025-12-19操作建议
Cytosorbents Corp当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在医疗设备与耗材行业排名128/208位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.25。中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cytosorbents Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
5.250
目标均价
+625.54%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cytosorbents Corp亮点
亮点风险
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
业绩增长期
公司处于发展阶段，最新年度总收入35.59M美元
估值合理
公司最新PE估值-3.50，处于3年历史合理位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值134.81K
活跃度增加
近期活跃度增加，过去20天平均换手率0.81
Cytosorbents Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cytosorbents Corp简介
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
公司代码CTSO
公司Cytosorbents Corp
CEOChan (Phillip P)
网址https://cytosorbents.com/
常见问题
Cytosorbents Corp(CTSO)的当前股价是多少？
Cytosorbents Corp(CTSO)的当前股价是 0.637。
Cytosorbents Corp的股票代码是什么？
Cytosorbents Corp的股票代码是CTSO。
Cytosorbents Corp股票的52周最高点是多少？
Cytosorbents Corp股票的52周最高点是1.610。
Cytosorbents Corp股票的52周最低点是多少？
Cytosorbents Corp股票的52周最低点是0.600。
Cytosorbents Corp的市值是多少？
Cytosorbents Corp的市值是39.99M。
Cytosorbents Corp的净利润是多少？
Cytosorbents Corp的净利润为-20.72M。
现在Cytosorbents Corp(CTSO)的股票是买入、持有还是卖出？
根据分析师评级，Cytosorbents Corp(CTSO)的总体评级为买入，目标价格为5.250。
Cytosorbents Corp(CTSO)股票的每股收益（EPS TTM）是多少
Cytosorbents Corp(CTSO)股票的每股收益（EPS TTM）是-0.182。
相关品种
-0.24%
+0.25%
+0.87%
+1.88%
+0.22%
-0.55%
+0.53%
+0.12%
+1.35%
-0.10%
-1.23%
-0.77%
+0.10%
+0.46%
+0.46%
+0.97%
+0.59%
+0.23%
+0.45%
+1.74%
